Fate Therapeutics (FATE) Leases (2019 - 2025)
Fate Therapeutics (FATE) has disclosed Leases for 7 consecutive years, with $41.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 10.53% year-over-year to $41.6 million, compared with a TTM value of $41.6 million through Dec 2025, down 10.53%, and an annual FY2025 reading of $41.6 million, down 10.53% over the prior year.
- Leases was $41.6 million for Q4 2025 at Fate Therapeutics, down from $42.4 million in the prior quarter.
- Across five years, Leases topped out at $70.7 million in Q4 2021 and bottomed at $41.6 million in Q4 2025.
- Average Leases over 5 years is $59.6 million, with a median of $63.2 million recorded in 2023.
- The sharpest move saw Leases rose 5.42% in 2021, then dropped 27.43% in 2025.
- Year by year, Leases stood at $70.7 million in 2021, then decreased by 6.58% to $66.1 million in 2022, then fell by 6.65% to $61.7 million in 2023, then decreased by 24.59% to $46.5 million in 2024, then decreased by 10.53% to $41.6 million in 2025.
- Business Quant data shows Leases for FATE at $41.6 million in Q4 2025, $42.4 million in Q3 2025, and $43.8 million in Q2 2025.